Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.

Researchers identified Janus kinase inhibitors as a promising treatment for the severe drug-induced skin condition toxic ...

The once-daily pill Rinvoq, also known as upadacitinib, has a new commercial circulating for 2024. The ad portrays people with moderate to severe eczema attempting to enjoy different pastimes like ...

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).

(RTTNews) - Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy of RINVOQ (upadacitinib) in moderate-to-severe ...

Results of a retrospective real-world study suggested no greater risk for major CV adverse events in patients treated with ...

The analysis evaluated the efficacy of upadacitinib (15 mg or 30 mg) in patients with moderate-to-severe atopic dermatitis (AD) stratified by the severity of disease in the head and neck region at ...

MoonLake Immunotherapeutics' stock has been volatile but is currently back to its previous year's level. Click here for more ...

Systemic JAK inhibitor therapy with tofacitinib was associated with the most favorable outcomes among patients with extensive vitiligo.

While there is no cure for ankylosing spondylitis (AS), a treatment regimen that consists of physical therapy and medication ...

“The heroes here tonight are not make-believe heroes from Marvel Comics, but real-life heroes who have made an impact on ...

New post-hoc analysis demonstrated efficacy of RINVOQ ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of severity in head and neck involvement, with results ...